Division of Trauma, Critical Care, Emergency Surgery, and Burns, Department of Surgery, College of Medicine, University of Arizona, Tucson, AZ.
Division of Acute Care Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD.
J Am Coll Surg. 2019 Jan;228(1):89-97. doi: 10.1016/j.jamcollsurg.2018.09.023. Epub 2018 Oct 22.
Patients with pelvic fractures are prone to venous thromboembolic (VTE) complications. Recent literature shows superiority of direct oral anticoagulants (DOACs) over low-molecular-weight heparin (LMWH) for thromboprophylaxis in patients undergoing orthopaedic operations. The aim of our study was to compare in-hospital outcomes for DOACs vs LMWH in patients with nonoperative pelvic fractures.
We performed a 2-year (2015 to 2016) analysis of the American College of Surgeons-Trauma Quality Improvement Program (ACS-TQIP) database. We included all adult patients with isolated blunt pelvic fractures who were managed nonoperatively and received thromboprophylaxis with either LMWH or DOACs (Factor-Xa inhibitor or direct thrombin inhibitor). Patients were divided into 2 groups based on receipt of DOACs vs LMWH and were propensity-score-matched in a 1:2 ratio to control for possible confounding factors. Primary outcomes were deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Secondary outcomes were pRBC transfusions, intervention for hemorrhage control, and in-hospital mortality after initiation of thromboprophylaxis.
We identified 20,692 patients with pelvic fractures. There were 7,312 patients with isolated pelvic fractures included, 852 of whom were matched (DOACs: 284; LMWH: 568). Mean age was 43.2 ± 15 years, median Injury Severity Score was 14 (range 10 to 18). Matched groups were similar in demographics, vital signs, injury parameters, and timing of initiation of thromboprophylaxis. Overall, 5.2% of patients had DVT, 1.4% PE, and 1.3% died. Patients who received DOACs were less likely to develop DVT (1.8% vs 6.9%, p < 0.01) compared with LMWH. There was no difference in PE (p = 0.85) or in-hospital mortality (p = 0.79) between the 2 groups. Similarly, there was no difference in post-prophylaxis blood transfusion, and post-prophylaxis intervention for hemorrhage control.
In patients with nonoperative pelvic fractures, DOACs were associated with a reduced rate of DVT vs LMWH without increasing the risk of bleeding complications. No association was found between the type of thromboprophylactic agent and rates of PE or in-hospital mortality.
骨盆骨折患者易发生静脉血栓栓塞(VTE)并发症。最近的文献表明,直接口服抗凝剂(DOACs)在预防接受骨科手术的患者发生血栓方面优于低分子量肝素(LMWH)。我们的研究目的是比较非手术治疗的骨盆骨折患者中 DOACs 与 LMWH 的住院治疗结局。
我们对美国外科医师学会创伤质量改进计划(ACS-TQIP)数据库进行了为期 2 年(2015 年至 2016 年)的分析。我们纳入了所有接受非手术治疗且接受 LMWH 或 DOACs(Xa 因子抑制剂或直接凝血酶抑制剂)进行血栓预防的单纯性钝性骨盆骨折的成年患者。根据接受 DOACs 与 LMWH 的情况,将患者分为两组,并按 1:2 的比例进行倾向评分匹配以控制可能的混杂因素。主要结局为深静脉血栓形成(DVT)和/或肺栓塞(PE)。次要结局为红细胞输注、出血控制干预以及开始血栓预防后的住院死亡率。
我们确定了 20692 例骨盆骨折患者。其中 7312 例为单纯性骨盆骨折,852 例患者接受了匹配(DOACs:284 例;LMWH:568 例)。平均年龄为 43.2±15 岁,中位数损伤严重度评分 14 分(范围 10 至 18 分)。匹配组在人口统计学、生命体征、损伤参数和开始预防血栓形成的时间方面相似。总体而言,5.2%的患者发生 DVT,1.4%发生 PE,1.3%死亡。与 LMWH 相比,接受 DOACs 的患者发生 DVT 的可能性较低(1.8%比 6.9%,p<0.01)。两组之间 PE 发生率(p=0.85)或住院死亡率(p=0.79)无差异。同样,预防治疗后输血和预防治疗后出血控制干预也没有差异。
在非手术治疗的骨盆骨折患者中,与 LMWH 相比,DOACs 可降低 DVT 的发生率,而不会增加出血并发症的风险。未发现预防治疗药物类型与 PE 发生率或住院死亡率之间存在关联。